OncRef

Clinical Trial: NCT03701334

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Novartis Pharmaceuticals
Information Provided By:Novartis
Last Update Posted:2026-10-09

Study Overview

Brief Summary

A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).

Official Title

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

Conditions

Early Breast Cancer

Intervention / Treatment

  • Drug: Ribociclib
  • Other: Endocrine Therapy (ET)

Other Study ID Numbers

  • CLEE011O12301C
  • 2023-510357-42-00
  • TRIO033
  • 2023

Start Date (Actual)

2018-12-07

Primary Completion Date (Estimated)

2030-05-29

Study Completion Date (Estimated)

2030-05-29

Enrollment (Actual)

5101

Study Type

Interventional

Phase

Phase 3